Canopy Growth Files 8-K on Material Agreement, Equity Sales

TL;DR

**Canopy Growth just reported new agreements and equity sales, watch for dilution.**

AI Summary

Canopy Growth Corporation filed an 8-K on January 19, 2024, reporting an event on January 18, 2024, related to entering a material definitive agreement and unregistered sales of equity securities. This filing indicates that Canopy Growth is actively managing its capital structure, potentially through new agreements or equity issuances. For investors, this matters because such actions can dilute existing shares, impact future profitability, or signal strategic shifts in the company's financial health and operational plans.

Why It Matters

This filing signals potential changes in Canopy Growth's financial structure, which could affect share value and future growth prospects for investors.

Risk Assessment

Risk Level: medium — The filing mentions unregistered sales of equity securities, which could lead to dilution for existing shareholders, increasing investment risk.

Analyst Insight

A smart investor would monitor subsequent filings or company announcements for specific details on the 'Material Definitive Agreement' and the 'Unregistered Sales of Equity Securities' to assess potential dilution and the strategic implications for Canopy Growth's financial health.

Key Players & Entities

• Canopy Growth Corporation (company) — registrant filing the 8-K
• January 18, 2024 (date) — date of the earliest event reported
• January 19, 2024 (date) — filing date of the 8-K
• 001-38496 (other) — Commission File Number
• CGC (other) — Trading Symbol for Common Shares
• Nasdaq Global Select Market (other) — exchange where Common Shares are registered

Forward-Looking Statements

• Canopy Growth will provide more details on the material definitive agreement and equity sales in future filings or press releases. (Canopy Growth Corporation) — high confidence, target: Q1 2024
• The unregistered sales of equity securities will lead to a short-term increase in outstanding shares. (Canopy Growth Corporation) — high confidence, target: Q1 2024

FAQ

Key Financial Figures

• $4.29 — e "Units") of the Company at a price of $4.29 per Unit in a private placement (the "P
• $35,000,000 — egate gross proceeds of approximately US$35,000,000. The Private Placement closed on Januar
• $4.83 — from the Company at a price equal to US$4.83. The Series A Warrants are currently ex
• $32.5 million — received net proceeds of approximately $32.5 million (assuming no exercise of Warrants). The

Filing Documents

• tm242252d3_8k.htm (8-K) — 35KB
• tm242252d3_ex4-1.htm (EX-4.1) — 131KB
• tm242252d3_ex4-2.htm (EX-4.2) — 132KB
• tm242252d3_ex10-1.htm (EX-10.1) — 286KB
• tm242252d3_ex10-2.htm (EX-10.2) — 96KB
• tm242252d3_ex99-1.htm (EX-99.1) — 14KB
• 0001104659-24-005221.txt ( ) — 1007KB
• cgc-20240118.xsd (EX-101.SCH) — 3KB
• cgc-20240118_lab.xml (EX-101.LAB) — 33KB
• cgc-20240118_pre.xml (EX-101.PRE) — 22KB
• tm242252d3_8k_htm.xml (XML) — 3KB

01

Item 1.01 Entry Into a Material Definitive Agreement. On January 18, 2024, Canopy Growth Corporation (the "Company"), entered into Subscription Agreements (collectively, the "Subscription Agreements") with certain institutional investors (collectively, the "Investors") pursuant to which the Company agreed sell to the Investors an aggregate of 8,158,510 units (each a "Unit" and, collectively, the "Units") of the Company at a price of $4.29 per Unit in a private placement (the "Private Placement") for aggregate gross proceeds of approximately US$35,000,000. The Private Placement closed on January 19, 2024 (the "Closing Date"). Each Unit is comprised of (a) one common share of the Company (a "Common Share") and (b)(i) one Series A Common Share purchase warrant (a "Series A Warrant") or (ii) one Series B Common Share purchase warrant (a "Series B Warrant" and, together with the Series A Warrants, the "Warrants"). Each Warrant entitles the holder to acquire one Common Share from the Company at a price equal to US$4.83. The Series A Warrants are currently exercisable and will remain exercisable for a period of five years from the Closing Date, and the Series B Warrants are exercisable for a period commencing on the date that is six-months following the Closing Date and ending on the date that is five years following such date. The Company has also agreed to provide the Investors with customary registration rights pursuant to the Registration Rights Agreement (as defined below). After the payment of the fees payable to the Placement Agents (as defined below) and estimated offering expenses payable by the Company in connection with the Private Placement, the Company received net proceeds of approximately $32.5 million (assuming no exercise of Warrants). The Company intends to use the net proceeds from the Private Placement to pay down debt as well as for working capital and other general corporate purposes. The Subscription Agreements include standard representations,

02 Unregistered Sales of

Item 3.02 Unregistered Sales of Equity Securities. The disclosures set forth in Item 1.01 above and the first paragraph of Item 8.01 below related to the Private Placement are incorporated by reference into this Item 3.02. The issuance of the Common Shares and the Warrants underlying the Units and the Common Shares underlying the Warrants were made in reliance on the exemption from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended.

01 Other Events

Item 8.01 Other Events. In connection with the Private Placement, the Company entered into an engagement letter with the Placement Agents (the "Engagement Letter"), pursuant to which the Company agreed to pay the Placement Agents a cash fee equal to 4.5% of the gross proceeds received by the Company in the Private Placement, in addition to reimbursement for reasonable expenses. The Engagement Letter contains customary representations, warranties, terms and conditions, including for indemnification of the Placement Agents by the Company. On January 18, 2024, the Company issued a press release announcing the Private Placement. A copy of the press release is attached to this Current Report as Exhibit 99.1 and is incorporated herein by reference.

01 Financial Statements

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Exhibit 4.1 Form of Series A Warrant. 4.2 Form of Series B Warrant. 10.1 * Form of Subscription Agreement, dated January 18, 2024. 10.2 * Registration Rights Agreement, dated as of January 19, 2024. 99.1 Press Release, dated January 18, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The registrant agrees to furnish supplementally a copy of all omitted exhibits and schedules to the SEC upon its request. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CANOPY GROWTH CORPORATION Dated: January 19, 2024 By: /s/ Judy Hong Judy Hong Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR